<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Allergy Asthma Clin Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Allergy Asthma Clin Immunol</journal-id><journal-title-group><journal-title>Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology</journal-title></journal-title-group><issn pub-type="ppub">1710-1484</issn><issn pub-type="epub">1710-1492</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39731198</article-id><article-id pub-id-type="pmc">PMC11681636</article-id><article-id pub-id-type="publisher-id">923</article-id><article-id pub-id-type="doi">10.1186/s13223-024-00923-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Allergic rhinitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rosenfield</surname><given-names>Lana</given-names></name><address><email>lanarosenfield@me.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Keith</surname><given-names>Paul K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Quirt</surname><given-names>Jaclyn</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Small</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ellis</surname><given-names>Anne K.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02gfys938</institution-id><institution-id institution-id-type="GRID">grid.21613.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9609</institution-id><institution>Department of Internal Medicine, </institution><institution>University of Manitoba, </institution></institution-wrap>Winnipeg, MB Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02fa3aq29</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution>Division of Clinical Immunology and Allergy, Department of Medicine, </institution><institution>McMaster University, </institution></institution-wrap>Hamilton, ON Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056jjra10</institution-id><institution-id institution-id-type="GRID">grid.414980.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9401 2774</institution-id><institution>Jewish General Hospital, </institution></institution-wrap>Montreal, QC Canada </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02y72wh86</institution-id><institution-id institution-id-type="GRID">grid.410356.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8331</institution-id><institution>Division of Allergy &#x00026; Immunology, Department of Medicine, </institution><institution>Queen&#x02019;s University, </institution></institution-wrap>Kingston, ON Canada </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>20</volume><issue>Suppl 3</issue><issue-sponsor>Publication of this supplement has been supported by ALK, Biocryst, CSL Behring, GSK, Miravo, Medexus, Novartis, Stallergenes Greer, and Takeda. The supporters had no involvement in the writing, development or review of any of the supplement articles. The articles have undergone the journal's standard peer review process for supplements. The Supplement Editors were not involved in the review of any articles they co-authored. The Editors are part of the journal's editorial board. No other competing interests were declared.</issue-sponsor><elocation-id>74</elocation-id><history><date date-type="received"><day>16</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Allergic rhinitis (AR) is a common disorder that is strongly linked to asthma and conjunctivitis. Classic symptoms include nasal congestion, nasal itch, rhinorrhea and sneezing. A thorough history, physical examination and assessment of allergen sensitization are important for establishing the diagnosis of AR. Intranasal corticosteroids and second-generation antihistamines are the mainstay of treatment. Allergen immunotherapy is an effective immune-modulating treatment for use in addition to or as an alternative to pharmacologic therapy. This article provides an overview on the pathophysiology, diagnosis, and appropriate management of AR.</p></abstract><abstract id="Abs2" abstract-type="highlights"><title>Key take-home messages</title><p id="Par67">
<list list-type="bullet"><list-item><p id="Par68">AR is strongly linked with asthma and conjunctivitis.</p></list-item><list-item><p id="Par69">Allergen skin testing is the best diagnostic test to confirm AR. However, serum-specific IgE testing is a reasonable alternative.</p></list-item><list-item><p id="Par70">Intranasal corticosteroids are the mainstay of treatment for most patients that present to physicians with AR. Second-generation oral antihistamines may also be used as first-line therapies.</p></list-item><list-item><p id="Par71">Allergen immunotherapy is an effective immune-modulating treatment in conjunction with or as an alternative to pharmacologic therapy.</p></list-item><list-item><p id="Par72">At any point in the management of patients with AR, referral to allergist should be considered for confirmatory diagnosis and treatment/management discussions.</p></list-item></list></p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Canadian Society of Allergy &#x00026; Clinical Immunology 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par15">Rhinitis is broadly defined as inflammation of the nasal mucosa. It is a common disorder that affects up to 40% of the population [<xref ref-type="bibr" rid="CR1">1</xref>]. Allergic rhinitis (AR) is the most common type of chronic rhinitis, affecting up to 20% of the Canadian population [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], and evidence suggests that the prevalence of the disorder is increasing [<xref ref-type="bibr" rid="CR4">4</xref>]. Severe AR has been associated with significant impairments in quality of life (QoL), sleep and work performance [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par16">In the past, AR was considered a disorder localized to the nose and nasal passages, but more recent evidence indicates that it may represent a component of a systemic airway disease involving the entire respiratory tract [<xref ref-type="bibr" rid="CR5">5</xref>]. There are several physiological, functional and immunological relationships between the upper (nose, nasal cavity, paranasal sinuses, Eustachian tube, pharynx and larynx) and lower (trachea, bronchial tubes, bronchioles and lungs) respiratory tracts. For example, both tracts contain a ciliated epithelium consisting of goblet cells that secrete mucous, which serves to filter the incoming air and protect structures within the airways. Furthermore, the submucosa of both the upper and lower airways includes a collection of blood vessels, mucous glands, supporting cells, nerves and inflammatory cells. Evidence has shown that allergen provocation of the upper airways not only leads to a local inflammatory response, but may also lead to inflammatory processes in the lower airways, and this is supported by the fact that rhinitis and asthma frequently coexist [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, AR and asthma appear to represent a combined airway inflammatory disease, and this needs to be considered to ensure the optimal assessment and management of patients with AR [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par17">Comprehensive and widely accepted Canadian guidelines for the diagnosis and treatment of AR were published in 2007 [<xref ref-type="bibr" rid="CR1">1</xref>]. This article provides an overview and update on the recommendations provided in these guidelines as well as a review of current literature related to the pathophysiology, diagnosis, and appropriate management of AR. Also included are conclusions from the &#x0201c;Focused Allergic Rhinitis Practice Parameter for Canada&#x0201d; published in 2024 [<xref ref-type="bibr" rid="CR7">7</xref>].</p></sec><sec id="Sec2"><title>Pathophysiology</title><p id="Par18">In AR, numerous inflammatory cells, including mast cells, CD4-positive T cells, B cells, macrophages, and eosinophils, infiltrate the nasal lining upon exposure to an inciting allergen (most commonly airborne dust mite particles, cockroach residues, animal dander, moulds, and pollens). In allergic individuals, the T cells infiltrating the nasal mucosa are predominantly T helper 2 (Th2) in nature and release cytokines (e.g., interleukin [IL]-3, IL-4, IL-5, and IL-13) that promote immunoglobulin E (IgE) production by plasma cells. Crosslinking of IgE bound to mast cells by allergens, in turn, triggers the release of mediators, such as histamine and leukotrienes, that are responsible for arteriolar dilation, increased vascular permeability, itching, rhinorrhea, mucous secretion, and smooth muscle contraction in the lung [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The mediators and cytokines released during the early phase of an immune response to an inciting allergen trigger a further cellular inflammatory response over the next 4 to 8&#x000a0;h (late-phase inflammatory response) which results in recurrent symptoms (usually nasal congestion) that often persist [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p></sec><sec id="Sec3"><title>Classification</title><p id="Par19">Rhinitis is classified into one of the following categories according to etiology: IgE-mediated (allergic), autonomic, infectious and idiopathic (unknown). Although the focus of this article is AR, a brief description of the other forms of rhinitis is provided in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Etiological classification of rhinitis [<xref ref-type="bibr" rid="CR1">1</xref>]</p></caption><graphic position="anchor" xlink:href="13223_2024_923_Tab1_HTML" id="MO010"/></table-wrap></p><p id="Par20">Traditionally, AR has been classified as seasonal (occurs during a specific season) or perennial (occurs throughout the year). However, not all patients fit into this classification scheme. For example, some allergic triggers, such as pollen, may be seasonal in cooler climates, but perennial in warmer climates, and patients with multiple &#x0201c;seasonal&#x0201d; allergies may have symptoms throughout most of the year [<xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, AR is now classified according to symptom duration (intermittent or persistent) and severity (mild, moderate or severe) (see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have defined &#x0201c;intermittent&#x0201d; AR as symptoms that are present less than 4&#x000a0;days per week or for less than 4 consecutive weeks, and &#x0201c;persistent&#x0201d; AR as symptoms that are present more than 4&#x000a0;days/week and for more than 4 consecutive weeks [<xref ref-type="bibr" rid="CR9">9</xref>]. Symptoms are considered mild when patients have no impairment in sleep and can perform normal activities (including work or school). Symptoms are considered moderate/severe if they significantly affect sleep or activities of daily living, and/or if they are perceived as bothersome. It is important to assess the severity and duration of symptoms as this will guide the management approach for individual patients [<xref ref-type="bibr" rid="CR1">1</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Classification of AR according to symptom duration and severity</p><p>(Adapted from Small et al. [<xref ref-type="bibr" rid="CR1">1</xref>], Bousquet et al. [<xref ref-type="bibr" rid="CR9">9</xref>])</p></caption><graphic xlink:href="13223_2024_923_Fig1_HTML" id="MO1"/></fig></p><p id="Par21">Two additional types of rhinitis have been classified that deserve some mention here&#x02014;occupational rhinitis and local allergic rhinitis.</p><sec id="Sec4"><title>Occupational rhinitis</title><p id="Par22">Occupational rhinitis is defined as an inflammatory disease of the nose characterized by intermittent or persistent symptoms that include airflow limitation, hypersecretion, sneezing and pruritus that are attributable to a particular work environment and not to stimuli encountered outside the workplace [<xref ref-type="bibr" rid="CR10">10</xref>]. Although the overall prevalence of occupational rhinitis is unknown, high-risk professions include laboratory or food-processing workers, veterinarians, farmers and workers in various manufacturing industries [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Occupational rhinitis usually develops within the first two years of employment. The condition may be IgE-mediated due to allergen sensitization, or due to exposure to respiratory irritants. Symptoms may develop immediately or several hours after exposure to the inciting stimuli. Often there are associated ocular and pulmonary symptoms. An evaluation of the patient suspected of having occupational rhinitis should include the usual history and physical examination (discussed later), as well as a site visit and skin testing or in vitro testing to inhalants. Treatment primarily involves avoiding exposure to the causative agent and pharmacotherapy as needed. There is little evidence to suggest that occupational rhinitis will progress to occupational asthma with ongoing exposure [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], although this is possible. Therefore, patients are generally not advised to leave their jobs if exposure cannot be eliminated but symptoms are adequately controlled.</p></sec><sec id="Sec5"><title>Local allergic rhinitis (LAR)</title><p id="Par23">LAR is a clinical entity characterized by a localized allergic response in the nasal mucosa in the absence of evidence of systemic atopy [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. By definition, patients with LAR have a history of symptoms on exposure to perennial and/or seasonal allergens, lack of sensitization found on skin testing or with specific IgE, and a positive nasal allergen provocation test to aeroallergen [<xref ref-type="bibr" rid="CR16">16</xref>]. It is important to note that the nasal allergen provocation test is not routinely available clinically.</p><p id="Par24">To date, there is no evidence to suggest that LAR is a precursor to AR since follow-up does not show the evolution to typical AR in these patients [<xref ref-type="bibr" rid="CR17">17</xref>]; however, patient follow-up may not have been long enough to detect this disease evolution. The implications for treatment of LAR are not well understood at this time, although some evidence suggests that allergen immunotherapy may be effective in this type of rhinitis [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p></sec></sec><sec id="Sec6"><title>Diagnosis and investigations</title><p id="Par25">AR is usually a long-standing condition. Patients suffering from AR often fail to recognize the impact of the disorder on QoL and functioning and, therefore, do not frequently seek medical attention. It is known that patients with perennial symptoms may accommodate and not perceive their symptoms as important [<xref ref-type="bibr" rid="CR18">18</xref>]. In addition, physicians may overlook regularly questioning patients about the disorder during routine visits [<xref ref-type="bibr" rid="CR1">1</xref>]. Screening for rhinitis is particularly important in asthmatic patients since studies have shown that rhinitis is present in up to 95% of patients with asthma [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par26">A thorough history and physical examination are the cornerstones of establishing the diagnosis of AR (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Allergy testing is also important for confirming that underlying allergies cause the rhinitis [<xref ref-type="bibr" rid="CR1">1</xref>]. Referral to an allergist should be considered if the diagnosis of AR is in question.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Components of a complete history and physical examination for suspected rhinitis [<xref ref-type="bibr" rid="CR1">1</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">History</th><th align="left">Physical examination</th></tr></thead><tbody><tr><td align="left"><p><italic>Personal</italic></p><p>&#x02022; Congestion</p><p>&#x02022; Nasal itch</p><p>&#x02022; Rhinorrhea</p><p>&#x02022; Sneezing</p><p>&#x02022; Eye involvement</p><p>&#x02022; Seasonality</p><p>&#x02022; Triggers</p><p><italic>Family</italic></p><p>&#x02022; Allergy</p><p>&#x02022; Asthma</p><p><italic>Environmental</italic></p><p>&#x02022; Pollens</p><p>&#x02022; Animals</p><p>&#x02022; Flooring/upholstery</p><p>&#x02022; Mould</p><p>&#x02022; Humidity</p><p>&#x02022; Tobacco or cannabis exposure</p><p><italic>Medication/drug use</italic></p><p>&#x02022; Beta-blockers</p><p>&#x02022; ASA</p><p>&#x02022; NSAIDs</p><p>&#x02022; ACE inhibitors</p><p>&#x02022; Hormone therapy</p><p>&#x02022; Recreational cocaine use</p><p><italic>Quality of life</italic></p><p>&#x02022; Rhinitis-specific questionnaire</p><p><italic>Comorbidities</italic></p><p>&#x02022; Asthma</p><p>&#x02022; Mouth breathing</p><p>&#x02022; Snoring&#x02009;&#x000b1;&#x02009;apnea</p><p>&#x02022; Impaired smell or taste</p><p>&#x02022; Sinus involvement</p><p>&#x02022; Otitis media</p><p>&#x02022; Nasal polyps</p><p>&#x02022; Conjunctivitis</p><p><italic>Response to previous interventions</italic></p><p>&#x02022; Avoidance measures</p><p>&#x02022; Saline nasal rinses</p><p>&#x02022; Second-generation oral antihistamines</p><p>&#x02022; Intranasal corticosteroids</p><p>&#x02022; Oral or intranasal decongestants</p><p>&#x02022; Oral corticosteroids</p></td><td align="left"><p><italic>Outward signs</italic></p><p>&#x02022; Mouth breathing</p><p>&#x02022; Rubbing the nose/transverse nasal crease</p><p>&#x02022; Frequent sniffling and/or throat clearing</p><p>&#x02022; Allergic shiners (dark circles under eyes)</p><p><italic>Nose</italic></p><p>&#x02022; Mucosal swelling, bleeding</p><p>&#x02022; Pale, thin secretions</p><p>&#x02022; Polyps or other structural abnormalities</p><p><italic>Ears</italic></p><p>&#x02022; Generally normal</p><p>&#x02022; Pneumatic otoscopy to assess for Eustachian tube dysfunction</p><p>&#x02022; Valsalva&#x02019;s maneuver to assess for fluid behind the ear drum</p><p><italic>Sinuses</italic></p><p>&#x02022; Palpation of sinuses for signs of tenderness</p><p>&#x02022; Maxillary tooth sensitivity</p><p><italic>Posterior oropharynx</italic></p><p>&#x02022; Postnasal drip</p><p>&#x02022; Lymphoid hyperplasia (&#x0201c;cobblestoning&#x0201d;)</p><p>&#x02022; Tonsillar hypertrophy</p><p><italic>Chest and skin</italic></p><p>&#x02022; Atopic disease</p><p>&#x02022; Wheezing</p></td></tr></tbody></table><table-wrap-foot><p><italic>ASA</italic> acetylsalicylic acid, <italic>NSAIDs</italic> non-steroidal anti-inflammatory drugs, <italic>ACE</italic> angiotensin-converting enzyme, <italic>OTC</italic> over-the-counter</p></table-wrap-foot></table-wrap></p><sec id="Sec7"><title>History</title><p id="Par27">During the history, patients will often describe the following classic symptoms of AR: nasal congestion, nasal itch, rhinorrhea and sneezing. Allergic conjunctivitis (inflammation of the membrane covering the white part of the eye) is also frequently associated with AR and symptoms generally include redness, tearing and itching of the eyes [<xref ref-type="bibr" rid="CR1">1</xref>]. Postnasal drip caused by nasal inflammation may cause cough or a sensation of sputum in the throat.</p><p id="Par28">A detailed history of the patient&#x02019;s home and work/school environments is recommended to determine potential triggers of AR. The environmental history should focus on common and potentially relevant allergens including pollens, furred animals, textile flooring/upholstery, tobacco or cannabis smoke, humidity levels at home, as well as other potential noxious substances that the patient may be exposed to at work or at home. The use of certain medications [e.g., beta-blockers, acetylsalicylic acid (ASA), non-steroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors, and hormone therapy] as well as the recreational use of cocaine can lead to symptoms of rhinitis and, therefore, patients should be asked about current or recent medication and drug use [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par29">The history should also include patient questioning regarding a family history of atopic disease, the impact of symptoms on QoL and the presence of comorbidities such as asthma, mouth breathing, snoring, sleep apnea, sinus involvement, otitis media (inflammation of the middle ear), or nasal polyps. Patients may attribute persistent nasal symptoms to a &#x0201c;constant cold&#x0201d; and, therefore, it is also important to document the frequency and duration of perceived upper respiratory viruses [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par30">Before seeking medical attention, patients often attempt using over-the-counter or other medications to manage their symptoms. Assessing patient response to such treatments may provide information that can aid in the diagnosis and subsequent management of AR. For example, symptom improvement with newer, second-generation antihistamines (discussed later) is strongly suggestive of an allergic etiology. However, it is important to note that response to first-generation antihistamines [e.g., diphenhydramine (Benadryl), brompheniramine maleate (Dimetane), chlorpheniramine maleate (Chlor-Tripolon), clemastine (Tavist-1)] does not imply an allergic etiology since the anticholinergic and sedative properties of these agents reduce rhinorrhea and may improve sleep quality regardless of whether the inflammation is allergic. Previous response to intranasal corticosteroids may also be suggestive of an allergic etiology, and likely indicates that such treatment will continue to be beneficial in the future [<xref ref-type="bibr" rid="CR1">1</xref>]. If an intranasal corticosteroid has previously been used, determining the length of time on treatment, compliance, and administration technique are important for assessing if the treatment trial was appropriate since it can take 2&#x02013;4&#x000a0;weeks to elicit an adequate response to intranasal steroids.</p><p id="Par31">Important elements of the history for patients with suspected AR are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.</p></sec><sec id="Sec8"><title>Physical examination</title><p id="Par32">The physical examination of patients with suspected AR should include an assessment of outward signs, the nose, ears, sinuses, posterior oropharynx (area of the throat that is at the back of the mouth), chest and skin (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Outward signs that may be suggestive of AR include: persistent mouth breathing, rubbing at the nose or an obvious transverse nasal crease, frequent sniffling or throat clearing, and allergic shiners (dark circles under the eyes that are due to nasal congestion). Examination of the nose typically reveals swelling of the nasal mucosa and pale, thin secretions. An internal endoscopic examination of the nose should also be considered to assess for structural abnormalities including septal deviation, nasal ulcerations, and nasal polyps [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par33">The ears generally appear normal in patients with AR; however, assessment for Eustachian tube dysfunction using a pneumatic otoscope should be considered. Valsalva&#x02019;s maneuver (increasing the pressure in the nasal cavity by attempting to blow out the nose while holding it shut) can also be used to assess for fluid behind the ear drum [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par34">The sinus examination should include palpation of the sinuses for evidence of tenderness and/or tapping of the maxillary teeth with a tongue depressor for evidence of sensitivity. The posterior oropharynx should also be examined for signs of postnasal drip (mucous accumulation in the back of the nose and throat), and the chest and skin should be examined carefully for signs of concurrent asthma (e.g., wheezing) or dermatitis respectively [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec><sec id="Sec9"><title>Diagnostic tests</title><p id="Par35">Although a thorough history and physical examination are required to establish the clinical diagnosis of rhinitis, further diagnostic testing is necessary to confirm that underlying allergies cause the rhinitis. Skin-prick testing is considered the primary method for identifying specific allergic triggers of rhinitis. It involves pricking the skin through a drop of commercial extract to introduce the extract into the epidermis. Within 15&#x02013;20&#x000a0;min, a wheal-and-flare response (an irregular blanched wheal surrounded by an area of redness) greater than the negative control will occur if the test is positive. Testing is typically performed using the allergens relevant to the patient&#x02019;s environment (e.g., pollen, animal dander, moulds and house dust mites). Antihistamines may interfere with the interpretation of skin tests and, therefore, should be stopped 5&#x02013;7&#x000a0;days before testing [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par36">A reasonable alternative to skin prick testing is the use of allergen-specific IgE tests [e.g., performed by immunosorbent assay&#x02014;previously performed by radioallergosorbent tests (RASTs)] that provide an in vitro measure of a patient&#x02019;s specific IgE levels against particular allergens. These in vitro tests can be performed in patients who cannot stop antihistamine therapy to allow for skin testing, those who are unable to come in-person for testing (e.g., during a pandemic or lack of availability of an allergist in their region), or those who also have extensive eczema which would preclude skin testing. Skin prick tests are generally considered to be more sensitive and cost effective than allergen-specific serum IgE tests, and have the further advantage of providing physicians and patients with immediate results. However, allergen-specific serum IgE is an acceptable alternative for guiding diagnosis and treatment [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Note that the allergen-specific serum IgE test may not be available to all patients or may be a higher cost to the patient depending on coverage.</p><p id="Par37">Testing patients for food allergies solely based on symptoms of AR is not recommended [<xref ref-type="bibr" rid="CR16">16</xref>]. Also, sinonasal imaging is not advised in patients with symptoms suggestive of AR alone [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec></sec><sec id="Sec10"><title>Treatment</title><p id="Par38">The treatment goal for AR is relief of symptoms. Therapeutic options available to achieve this goal include avoidance measures, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays, leukotriene receptor antagonists (LTRAs), and allergen immunotherapy. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> provides a simplified, stepwise algorithm for the treatment of AR [<xref ref-type="bibr" rid="CR7">7</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>A simplified, stepwise algorithm for the treatment of AR. The choice of therapeutic intervention should be a shared decision-making process involving both the patient and the prescriber, with importance placed on balancing factors such as disease severity, therapy safety, and cost. <italic>IgE</italic> immunoglobulin E</p><p>(Reproduced from Ellis et al. 2024 [<xref ref-type="bibr" rid="CR7">7</xref>])</p></caption><graphic xlink:href="13223_2024_923_Fig2_HTML" id="MO2"/></fig></p><p id="Par39">Other therapies that may be useful in select patients include decongestants and oral corticosteroids. AR and asthma appear to represent a combined airway inflammatory disease, making treatment of asthma an important consideration in patients with AR. At any point in management, referral to allergist should be considered for confirmatory diagnosis and treatment/management discussions.</p><sec id="Sec11"><title>Allergen avoidance</title><p id="Par40">The first-line treatment of AR involves the avoidance of relevant allergens (e.g., house dust mites, moulds, pets, pollens) and irritants (e.g., tobacco smoke) to the extent possible. Patients allergic to house dust mites should be instructed to use allergen-impermeable covers for bedding and to keep the relative humidity in the home below 50% (to inhibit mite growth). However, the humidity level should not be below 30% as this can be irritating to the respiratory mucosa and increase the risk of bacterial infections [<xref ref-type="bibr" rid="CR25">25</xref>]. Pollen and outdoor mould exposure can be reduced by keeping windows closed, using window screen filters, using an air conditioner, and limiting the amount of time spent outdoors during peak pollen seasons. For patients allergic to animal dander, removal of the animal from the home is recommended and usually results in a significant reduction in symptoms within 4&#x02013;6&#x000a0;months [<xref ref-type="bibr" rid="CR1">1</xref>]. However, compliance with this recommendation is poor and, therefore, the use of high-efficiency particulate air (HEPA) filters and restricting the animal from the bedroom or to the outdoors may be needed to attempt to decrease allergen levels. Measures for reducing exposure to mould allergens include cleaning with fungicides, dehumidification to less than 50%, remediation of any water damage, and HEPA filtration. These avoidance strategies can effectively improve the symptoms of AR, and patients should be advised to use a combination of measures for optimal results [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec><sec id="Sec12"><title>Sterile nasal saline</title><p id="Par41">Nasal irrigation with sterile nasal saline has been shown to improve symptoms and QoL while decreasing the requirement for medication in patients with AR [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]<italic>.</italic> It can also help with nasal moisture and clearing of mucus [<xref ref-type="bibr" rid="CR28">28</xref>]. Sterile nasal saline is an easy-to-use, low-cost option which patients can prepare themselves, without the potential side effects seen with pharmacotherapy [<xref ref-type="bibr" rid="CR29">29</xref>]. Due to the risk of transmission of microbial organisms, if tap water is used for nasal irrigation, it should be boiled (1 to 5&#x000a0;min) and then cooled [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec13"><title>Antihistamines</title><p id="Par42">Second-generation oral antihistamines, such as desloratadine (Aerius), fexofenadine (Allegra), loratadine (Claritin), cetirizine (Reactine), bilastine (Blexten) and rupatadine (Rupall), can be used as first-line therapies for patients with AR [<xref ref-type="bibr" rid="CR7">7</xref>]. Bilastine and rupatadine are available by prescription only (see Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> for a list of second-generation antihistamines and their recommended dosing regimens).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Overview of pharmacologic treatment options for AR</p></caption><graphic position="anchor" xlink:href="13223_2024_923_Tab3_HTML" id="MO011"/></table-wrap></p><p id="Par43">Second-generation oral antihistamines have been found to effectively reduce sneezing, itching and rhinorrhea when taken regularly at the time of maximal symptoms or before exposure to an allergen. While they are less efficacious than intranasal corticosteroids (discussed below), they may be the preferred option for patients based on preference [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par44">Although the older (first-generation) sedating antihistamines (e.g., diphenhydramine, chlorpheniramine) are also effective in relieving symptoms, they have been shown to negatively impact cognition and functioning [<xref ref-type="bibr" rid="CR1">1</xref>]. Because of this, prescribing first-generation antihistamines to patients with AR is not recommended [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec14"><title>Intranasal corticosteroids</title><p id="Par45">Intranasal corticosteroids are a first-line therapy for patients with AR and they can be used alone or in combination with oral antihistamines [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. When used regularly and correctly, intranasal corticosteroids effectively reduce inflammation of the nasal mucosa and improve mucosal pathology. Studies and meta-analyses have shown that intranasal corticosteroids are superior to antihistamines and LTRAs in controlling the symptoms of AR, including nasal congestion, and rhinorrhea [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. They have also been shown to improve ocular symptoms and reduce lower airway symptoms in patients with concurrent asthma and AR [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par46">The intranasal corticosteroids approved in Canada are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and include fluticasone furoate (Avamys), beclomethasone (Beconase), fluticasone propionate (Flonase), triamcinolone acetonide (Nasacort), mometasone furoate (Nasonex), ciclesonide (Omnaris) and budesonide (Rhinocort). Since proper application of the nasal spray is required for optimal clinical response, patients should be counseled on the appropriate use of these intranasal devices. Ideally, intranasal corticosteroids are best started just prior to exposure to relevant allergens and, because their peak effect may take several days to develop, they should be used regularly [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par47">The most common side effects of intranasal corticosteroids are nasal irritation and stinging. These side effects can usually be prevented by aiming the spray slightly away from the nasal septum [<xref ref-type="bibr" rid="CR1">1</xref>]. Evidence suggests that intranasal beclomethasone and triamcinolone, but not other intranasal corticosteroids, may slow growth in children compared to placebo, however, long-term studies examining the impact of usual doses of intranasal beclomethasone on growth are lacking [<xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par48">It is important to note that most patients with AR presenting to their primary-care physician have moderate-to-severe symptoms and will require an intranasal corticosteroid. Bousquet et al. noted improved outcomes in patients with moderate-to-severe symptoms treated with a combination of these agents [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec><sec id="Sec15"><title>Combination intranasal corticosteroid and antihistamine nasal spray</title><p id="Par49">If intranasal corticosteroids are not effective, a combination intranasal corticosteroid/antihistamine spray can be tried, such as combination fluticasone propionate/azelastine hydrochloride (Dymista) or olopatadine hydrochloride/mometasone furoate monohydrate (Ryaltris). Combination intranasal corticosteroid/antihistamine sprays have been shown to be effective within minutes [<xref ref-type="bibr" rid="CR32">32</xref>], and more effective than the individual components with a safety profile similar to intranasal corticosteroids [<xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>]. Combination intranasal corticosteroid/antihistamine sprays are also superior to oral antihistamines used along with intranasal nasal steroids [<xref ref-type="bibr" rid="CR7">7</xref>]. However, it is unknown whether there are any differences in efficacy between the two approaches after long-term use.</p></sec><sec id="Sec16"><title>Leukotriene receptor antagonists (LTRAs)</title><p id="Par50">The LTRAs montelukast and zafirlukast are also effective in the treatment of AR; however, they do not appear to be as effective as intranasal corticosteroids [<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. Although one short-term study found the combination of LTRAs and antihistamines to be as effective as intranasal corticosteroids [<xref ref-type="bibr" rid="CR53">53</xref>], longer-term studies have found intranasal corticosteroids to be more effective than the combination for reducing nighttime and nasal symptoms [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Currently montelukast is the only LTRA indicated for the treatment of AR in adults in Canada.</p><p id="Par51">LTRAs should be considered when alternate therapies such as oral antihistamines, intranasal corticosteroids and/or combination corticosteroid/antihistamine sprays are not well tolerated or are insufficient/ineffective in controlling the symptoms of AR [<xref ref-type="bibr" rid="CR16">16</xref>]. LTRAs have been shown to improve nighttime control of rhinitis symptoms [<xref ref-type="bibr" rid="CR7">7</xref>]. If a patient has co-morbid asthma, then an LTRA may be of benefit for both conditions [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. LTRAs confer a risk of serious neuropsychiatric events, particularly in those under 6&#x000a0;years of age [<xref ref-type="bibr" rid="CR7">7</xref>]. If prescribed, patients should be monitored for these symptoms [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec17"><title>Allergen immunotherapy</title><p id="Par52">Allergen immunotherapy, which involves the subcutaneous or sublingual administration of the patient&#x02019;s relevant allergens, is an option for patients who do not achieve symptom control with pharmacotherapy or who prefer this form of therapy [<xref ref-type="bibr" rid="CR7">7</xref>] (see <italic>Allergen Immunotherapy</italic> article in this supplement). It can be used as an alternative or add-on to the pharmacological therapies described above, and it is particularly effective in patients with intermittent (seasonal) AR caused by pollens, including tree, grass and ragweed pollens [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>]. Allergen immunotherapy has also been shown to be effective for the treatment of AR caused by house dust mites, Alternaria, cockroach, and cat and dog dander (although it should be noted that therapeutic doses of dog allergen are difficult to attain with the allergen extracts available in Canada). The effect of allergen immunotherapy varies depending on the allergen administered.</p><p id="Par53">In subcutaneous allergen immunotherapy (SCIT), gradually increasing quantities of the patient&#x02019;s relevant allergens are injected over time until a dose is reached that is effective in inducing immunologic tolerance to the allergen. Typically, SCIT is given on a perennial basis with weekly incremental increases in dose over the course of 6&#x02013;8&#x000a0;months, followed by maintenance injections of the maximum tolerated dose every 3 to 4&#x000a0;weeks for 3 to 5&#x000a0;years. After this period, many patients experience a prolonged, protective effect and, therefore, consideration can be given to stopping therapy. Pre-seasonal subcutaneous preparations that are administered for 4&#x02013;12&#x000a0;weeks on an annual basis are also available but are currently difficult to access in Canada [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par54">Sublingual immunotherapy (SLIT) is an alternative way of desensitizing patients and involves placing a tablet of allergen extract under the tongue for 1 to 2&#x000a0;min until it is dissolved. It is currently available for the treatment of tree, grass, ragweed and dust mite allergy. At present, five sublingual tablet immunotherapy products are available in Canada: Oralair&#x000ae;, Grastek&#x000ae; (both targeting grass pollen), Ragwitek&#x000ae; (ragweed) Itulatek&#x000ae; (birch tree), and Acarizax&#x02122; (dust mites) [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref>]. SLIT should only be administered using these Health Canada-approved products.</p><p id="Par55">SLIT offers multiple potential benefits over the subcutaneous route including the comfort of avoiding injections, the convenience of home administration, and a favourable safety profile. The most common side effects of SLIT are local reactions such as oral pruritus, throat irritation, and ear pruritus [<xref ref-type="bibr" rid="CR57">57</xref>]. These symptoms typically resolve after the first week of therapy. There is a very small risk of more severe systemic allergic reactions with this type of immunotherapy and, therefore, some allergists may offer the patient an epinephrine auto-injector in case a reaction occurs at home. However, the risk of systemic allergic reactions is much lower with SLIT compared to traditional injections (SCIT) [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par56">Both SCIT and SLIT are effective treatment options, but there is insufficient data to determine the benefit of one over the other. Shared decision making with the patient that takes into account factors such as cost, risk and practical considerations can help guide which is better suited for an individual patient [<xref ref-type="bibr" rid="CR7">7</xref>]. Since both forms of immunotherapy carry a risk of anaphylactic reactions, they should only be prescribed by physicians who are adequately trained in the treatment of allergy and who are equipped to manage possible life-threatening anaphylaxis [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par57">Evidence suggests that at least 3 years of allergen immunotherapy (SCIT or SLIT) provides beneficial effects in patients with AR that can persist for several years after discontinuation of therapy [<xref ref-type="bibr" rid="CR64">64</xref>&#x02013;<xref ref-type="bibr" rid="CR70">70</xref>]. In Canada, most allergists consider stopping immunotherapy after 5 years of adequate treatment. Recent data has made it clear that only 2 years of immunotherapy, either via the subcutaneous or sublingual route, is not sufficient to provide long-lasting effects [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>].</p><p id="Par58">Both forms of immunotherapy are contraindicated in patients with severe, unstable or uncontrolled asthma, and should ideally be avoided in patients on beta-blocker therapy. SLIT is contraindicated in those with active oral inflammation or sores or those with eosinophilic esophagitis [<xref ref-type="bibr" rid="CR57">57</xref>].</p></sec><sec id="Sec18"><title>Other therapeutic options</title><p id="Par59">Oral and intranasal decongestants (e.g., pseudoephedrine, phenylephrine) are useful for relieving nasal congestion in patients with AR. However, the side-effect profile associated with oral decongestants (i.e., agitation, insomnia, headache, palpitations) may limit their long-term use. Furthermore, these agents are contraindicated in patients with uncontrolled hypertension and severe coronary artery disease. Prolonged use of intranasal decongestants carries the risk of rhinitis medicamentosa (rebound nasal congestion) [<xref ref-type="bibr" rid="CR72">72</xref>] and, therefore, use should be limited to the short term [<xref ref-type="bibr" rid="CR16">16</xref>]. In patients who do not experience benefits with intranasal corticosteroids alone or a combination intranasal corticosteroid/antihistamine, intranasal decongestants in combination with intranasal corticosteroids for up to 4&#x000a0;weeks (but ideally no longer than a few days) may be considered [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par60">Oral corticosteroids have also been shown to be effective in patients with severe AR that is refractory to treatment with oral antihistamines and intranasal corticosteroids [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, a short course (5&#x02013;7&#x000a0;days) of oral corticosteroids may be considered in these patients [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par61">Although not as effective as intranasal corticosteroids, intranasal sodium cromoglycate (Cromolyn) has been shown to reduce sneezing, rhinorrhea and nasal itching and, therefore, it is a reasonable therapeutic option for some patients [<xref ref-type="bibr" rid="CR1">1</xref>]. The anti-IgE antibody, omalizumab, has also been shown to be effective in seasonal AR [<xref ref-type="bibr" rid="CR1">1</xref>], however, it is not currently approved for the treatment of AR.</p><p id="Par62">Surgical therapy may be helpful for select patients with rhinitis, polyposis, or chronic sinus disease that is refractory to medical treatment [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec><sec id="Sec19"><title>Complementary and alternative medicines (CAM)</title><p id="Par63">Given the popularity of complementary and alternative medicines (CAM) in the general population, it is reasonable for physicians to ask patients about their use of CAM in a nonjudgmental manner. Given the limited number of well-designed clinical trials examining the efficacy of CAM in AR, it is difficult for clinicians to evaluate these therapies and provide guidance.</p><p id="Par64">Various CAM have been used for the management of AR, including&#x000a0;traditional Chinese&#x000a0;medicines, acupuncture, homeopathy, and herbal&#x000a0;therapies [<xref ref-type="bibr" rid="CR73">73</xref>]. At present, there is insufficient evidence to support the use of CAM for the management of AR [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec20"><title>Special considerations: pregnancy</title><p id="Par65">It is important to note that AR may worsen during pregnancy and, as a result, may necessitate pharmacologic treatment. The benefit-to-risk ratio of pharmacological agents for AR needs to be considered before recommending any medical therapy to pregnant women. Sterile nasal saline is a first-line option as it is safe and effective in pregnant women [<xref ref-type="bibr" rid="CR16">16</xref>]. Intranasal sodium cromoglycate can be used for AR in pregnancy since no teratogenic effects have been noted with the cromones in humans or animals. With the exception of triamcinolone, most intranasal corticosteroids are safe in pregnancy, with newer data supporting the safety of mometasone and fluticasone [<xref ref-type="bibr" rid="CR16">16</xref>]. Antihistamines may also be considered for AR in pregnancy, specifically cetirizine and loratadine. Oral decongestants should not be used in pregnancy, especially in the first trimester [<xref ref-type="bibr" rid="CR16">16</xref>]. Starting or increasing allergen immunotherapy during pregnancy is not recommended because of the risk of anaphylaxis for the mother and potential complications to the fetus. However, maintenance doses are considered to be safe and effective during pregnancy [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec></sec><sec id="Sec21"><title>Conclusions</title><p id="Par66">AR is a common disorder that can significantly impact patient QoL. The diagnosis is made through a comprehensive history and physical examination. Further diagnostic testing using skin-prick tests or allergen-specific IgE tests are helpful to confirm that underlying allergen sensitization is the cause of rhinitis. Many therapeutic options are available for the treatment of AR that are effective and well tolerated, including intranasal corticosteroids, second-generation oral antihistamines and allergen immunotherapy.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACE</term><def><p id="Par2">Angiotensin-converting enzyme</p></def></def-item><def-item><term>AR</term><def><p id="Par3">Allergic rhinitis</p></def></def-item><def-item><term>ARIA</term><def><p id="Par4">Allergic Rhinitis and its Impact on Asthma</p></def></def-item><def-item><term>ASA</term><def><p id="Par5">Acetylsalicylic acid</p></def></def-item><def-item><term>CAM</term><def><p id="Par6">Complementary and alternative medicines</p></def></def-item><def-item><term>HEPA</term><def><p id="Par7">High-efficiency particulate air</p></def></def-item><def-item><term>IgE</term><def><p id="Par8">Immunoglobulin E</p></def></def-item><def-item><term>IL</term><def><p id="Par9">Interleukin</p></def></def-item><def-item><term>LAR</term><def><p id="Par10">Local allergic rhinitis</p></def></def-item><def-item><term>NSAIDs</term><def><p id="Par11">Non-steroidal anti-inflammatory drugs</p></def></def-item><def-item><term>LTRAs</term><def><p id="Par12">Leukotriene receptor antagonists</p></def></def-item><def-item><term>QoL</term><def><p id="Par13">Quality of life</p></def></def-item><def-item><term>Th2</term><def><p id="Par14">T helper 2</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This article is an update to the <italic>Allergic Rhinitis</italic> article authored by Dr. Peter Small, Dr. Paul K. Keith and Dr. Harold Kim that originally appeared in the supplement entitled, Practical Guide to Allergy and Immunology in Canada, which was published in Allergy, Asthma &#x00026; Clinical Immunology in 2018 (available at: <ext-link ext-link-type="uri" xlink:href="https://aacijournal.biomedcentral.com/articles/supplements/volume-14-supplement-2">https://aacijournal.biomedcentral.com/articles/supplements/volume-14-supplement-2</ext-link>) [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>The authors thank Julie Tasso for her editorial services and assistance in the preparation of this manuscript.</p><sec id="d33e1047"><title>About this supplement</title><p>This article has been published as part of Allergy, Asthma &#x00026; Clinical Immunology, Volume 20 Supplement 03, 2024: Practical Guide for Allergy and Immunology in Canada 2024. The full contents of the supplement are available at <ext-link ext-link-type="uri" xlink:href="https://aacijournal.biomedcentral.com/articles/supplements/volume-20-supplement-3">https://aacijournal.biomedcentral.com/articles/supplements/volume-20-supplement-3</ext-link>.</p></sec></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>The authors confirm contribution to the paper as follows: conception and design: LR; acquisition of data: LR, PKK, JQ, PS; analysis and interpretation of data: LR, PKK, JQ, PS, AKE;&#x000a0;drafting of manuscript: LR, PKK, JQ, PS; critical revision and editing of manuscript: LR, PKK, JQ, PS, AKE. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Publication of this supplement has been supported by ALK, Biocryst, CSL Behring, GSK, Miravo, Medexus, Novartis, Stallergenes Greer, and Takeda. The supporters had no involvement in the writing, development or review of this manuscript.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Data sharing not applicable to this article as no datasets were generated or analyzed during the development of this review.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par73">Ethics approval and consent to participate are not applicable to this review article.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par74">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par75">L. Rosenfield has received honoraria from Miravo, Regeneron and the CSACI and has been a member of an advisory board or speaker&#x02019;s bureau for ALK. PK Keith has participated in advisory boards for ALK-Abello, AstraZeneca, Bausch Health, CSL Behring, GlaxoSmithKline, LEO Pharma, Miravo, Merck, Novartis, Sanofi, Takeda and Valeo. He has been a speaker for ALK-Abello,&#x000a0;Bausch, GlaxoSmithKline, Medexus, Novartis, and Sanofi. His institution has received research grants from CSL Behring and Takeda. He has also served as a consultant to Bayer LLC, CADTH, and the Canadian Pharmacists Association. J. Quirt has participated in advisory boards for Aralez and Sanofi. A.K. Ellis has participated in advisory boards for ALK-Abello, AstraZeneca, Bausch Health, LEO Pharma, Miravo, Merck, Novartis, has been a speaker for ALK-Abello, AstraZeneca, Bausch, Miravo, Medexus, Mylan, Novartis, Pfizer, Sanofi, StallergenesGreer and Regeneron. Her institution has received research grants from ALK Abello, Aralez, AstraZeneca, Bayer LLC, Medexus, Novartis, Sanofi and Regeneron. She has also served as an independent consultant to Bayer LLC, Pharming, and Regeneron. P. Small has nothing to disclose.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>P</given-names></name><name><surname>Frenkiel</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Boisvert</surname><given-names>P</given-names></name><name><surname>Bouchard</surname><given-names>J</given-names></name><name><surname>Carr</surname><given-names>S</given-names></name><etal/></person-group><article-title>The Canadian Rhinitis Working Group: Rhinitis. A practical and comprehensive approach to assessment and therapy</article-title><source>J Otolaryngol</source><year>2007</year><volume>36</volume><issue>Suppl 1</issue><fpage>S5</fpage><lpage>S27</lpage><pub-id pub-id-type="doi">10.2310/7070.2006.X002</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Small P, Frenkiel S, Becker A, Boisvert P, Bouchard J, Carr S, et al. The Canadian Rhinitis Working Group: Rhinitis. A practical and comprehensive approach to assessment and therapy. J Otolaryngol. 2007;36(Suppl 1):S5&#x02013;27.</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Canuel</surname><given-names>M</given-names></name><name><surname>Lebel</surname><given-names>G</given-names></name></person-group><article-title>Epidemiology of allergic rhinitis in Quebec: from a 2008 population-based survey</article-title><source>Chronic Dis Injuries Canada</source><year>2014</year><volume>34</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.24095/hpcdp.34.2/3.11</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Canuel M, Lebel G. Epidemiology of allergic rhinitis in Quebec: from a 2008 population-based survey. Chronic Dis Injuries Canada. 2014;34:163&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname><given-names>PK</given-names></name><name><surname>Desrosiers</surname><given-names>M</given-names></name><name><surname>Laister</surname><given-names>T</given-names></name><name><surname>Schellenberg</surname><given-names>RR</given-names></name><name><surname>Waserman</surname><given-names>S</given-names></name></person-group><article-title>The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients</article-title><source>Allergy Asthma Clin Immunol</source><year>2012</year><volume>8</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1710-1492-8-7</pub-id><pub-id pub-id-type="pmid">22656186</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy Asthma Clin Immunol. 2012;8:7.<pub-id pub-id-type="pmid">22656186</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Dykewicz</surname><given-names>MS</given-names></name><name><surname>Hamilos</surname><given-names>DL</given-names></name></person-group><article-title>Rhinitis and sinusitis</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>125</volume><fpage>S103</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.12.989</pub-id><pub-id pub-id-type="pmid">20176255</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010;125:S103-115.<pub-id pub-id-type="pmid">20176255</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>P</given-names></name><name><surname>Keith</surname><given-names>PK</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name></person-group><article-title>Allergic rhinitis</article-title><source>Allergy Asthma Clin Immunol</source><year>2018</year><volume>14</volume><issue>Suppl 2</issue><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s13223-018-0280-7</pub-id><pub-id pub-id-type="pmid">30263033</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):51.<pub-id pub-id-type="pmid">30263033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Bourdin</surname><given-names>A</given-names></name><name><surname>Gras</surname><given-names>D</given-names></name><name><surname>Vachier</surname><given-names>I</given-names></name><name><surname>Chanez</surname><given-names>P</given-names></name></person-group><article-title>Upper airway 1: allergic rhinitis and asthma: united disease through epithelial cells</article-title><source>Thorax</source><year>2009</year><volume>64</volume><issue>11</issue><fpage>999</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1136/thx.2008.112862</pub-id><pub-id pub-id-type="pmid">19864543</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bourdin A, Gras D, Vachier I, Chanez P. Upper airway 1: allergic rhinitis and asthma: united disease through epithelial cells. Thorax. 2009;64(11):999&#x02013;1004.<pub-id pub-id-type="pmid">19864543</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>AK</given-names></name><name><surname>Cook</surname><given-names>V</given-names></name><name><surname>Keith</surname><given-names>PK</given-names></name><name><surname>Mace</surname><given-names>SR</given-names></name><name><surname>Moote</surname><given-names>W</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>A</given-names></name><etal/></person-group><article-title>Focused allergic rhinitis practice parameter for Canada</article-title><source>Allergy Asthma Clin Immunol</source><year>2024</year><volume>20</volume><issue>1</issue><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s13223-024-00899-3</pub-id><pub-id pub-id-type="pmid">39118164</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ellis AK, Cook V, Keith PK, Mace SR, Moote W, O&#x02019;Keefe A, et al. Focused allergic rhinitis practice parameter for Canada. Allergy Asthma Clin Immunol. 2024;20(1):45.<pub-id pub-id-type="pmid">39118164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Mace</surname><given-names>S</given-names></name></person-group><article-title>An approach to allergic rhinitis</article-title><source>Allergy Rounds</source><year>2009</year><volume>1</volume><fpage>1</fpage></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lee P, Mace S. An approach to allergic rhinitis. Allergy Rounds. 2009;1:1.</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Khaltaev</surname><given-names>N</given-names></name><name><surname>Cruz</surname><given-names>AA</given-names></name><name><surname>Denburg</surname><given-names>J</given-names></name><name><surname>Fokkens</surname><given-names>WJ</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name><etal/></person-group><article-title>World Health Organization; GA(2)LEN; AllerGen: allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)</article-title><source>Allergy</source><year>2008</year><volume>63</volume><issue>Suppl 86</issue><fpage>8</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2007.01620.x</pub-id><pub-id pub-id-type="pmid">18331513</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. World Health Organization; GA(2)LEN; AllerGen: allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8&#x02013;160.<pub-id pub-id-type="pmid">18331513</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Moscato</surname><given-names>G</given-names></name><name><surname>Vandenplas</surname><given-names>O</given-names></name><name><surname>Van Wijk</surname><given-names>RG</given-names></name><name><surname>Malo</surname><given-names>JL</given-names></name><name><surname>Perfetti</surname><given-names>L</given-names></name><name><surname>Quirce</surname><given-names>S</given-names></name><name><surname>Walusiak</surname><given-names>J</given-names></name><name><surname>Castano</surname><given-names>R</given-names></name><name><surname>Pala</surname><given-names>G</given-names></name><name><surname>Gautrin</surname><given-names>D</given-names></name><name><surname>De Groot</surname><given-names>H</given-names></name><name><surname>Folletti</surname><given-names>I</given-names></name><name><surname>Yacoub</surname><given-names>MR</given-names></name><name><surname>Siracusa</surname><given-names>A</given-names></name><collab>European Academy of Allergology and Clinical Immunology</collab></person-group><article-title>EAACI position paper on occupational rhinitis</article-title><source>Respir Res</source><year>2009</year><volume>10</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-10-16</pub-id><pub-id pub-id-type="pmid">19257881</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Moscato G, Vandenplas O, Van Wijk RG, Malo JL, Perfetti L, Quirce S, Walusiak J, Castano R, Pala G, Gautrin D, De Groot H, Folletti I, Yacoub MR, Siracusa A, European Academy of Allergology and Clinical Immunology. EAACI position paper on occupational rhinitis. Respir Res. 2009;10:16.<pub-id pub-id-type="pmid">19257881</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Seong</surname><given-names>WK</given-names></name><name><surname>Son</surname><given-names>TJ</given-names></name><name><surname>Rhee</surname><given-names>CS</given-names></name></person-group><article-title>Allergic rhinitis in laboratory animal workers and its risk factors</article-title><source>Ann Allergy Asthma Immunol</source><year>2009</year><volume>102</volume><issue>5</issue><fpage>373</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/S1081-1206(10)60507-8</pub-id><pub-id pub-id-type="pmid">19492657</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jang JH, Kim DW, Kim SW, Kim DY, Seong WK, Son TJ, Rhee CS. Allergic rhinitis in laboratory animal workers and its risk factors. Ann Allergy Asthma Immunol. 2009;102(5):373&#x02013;7.<pub-id pub-id-type="pmid">19492657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Moscato</surname><given-names>G</given-names></name><name><surname>Siracusa</surname><given-names>A</given-names></name></person-group><article-title>Rhinitis guidelines and implications for occupational rhinitis</article-title><source>Curr Opin Allergy Clin Immunol</source><year>2009</year><volume>9</volume><issue>2</issue><fpage>110</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1097/ACI.0b013e328328cfe7</pub-id><pub-id pub-id-type="pmid">19326505</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Moscato G, Siracusa A. Rhinitis guidelines and implications for occupational rhinitis. Curr Opin Allergy Clin Immunol. 2009;9(2):110&#x02013;5.<pub-id pub-id-type="pmid">19326505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Rond&#x000f3;n</surname><given-names>C</given-names></name><name><surname>Campo</surname><given-names>P</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name><name><surname>Fokkens</surname><given-names>WJ</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Powe</surname><given-names>DG</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><name><surname>Blanca</surname><given-names>M</given-names></name></person-group><article-title>Local allergic rhinitis: concept, pathophysiology, and management</article-title><source>J Allergy Clin Immunol</source><year>2012</year><volume>129</volume><issue>6</issue><fpage>1460</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2012.02.032</pub-id><pub-id pub-id-type="pmid">22516477</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Rond&#x000f3;n C, Campo P, Togias A, Fokkens WJ, Durham SR, Powe DG, Mullol J, Blanca M. Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol. 2012;129(6):1460&#x02013;7.<pub-id pub-id-type="pmid">22516477</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Campo</surname><given-names>P</given-names></name><name><surname>Rond&#x000f3;n</surname><given-names>C</given-names></name><name><surname>Gould</surname><given-names>HJ</given-names></name><name><surname>Barrionuevo</surname><given-names>E</given-names></name><name><surname>Gevaert</surname><given-names>P</given-names></name><name><surname>Blanca</surname><given-names>M</given-names></name></person-group><article-title>Local IgE in non-allergic rhinitis</article-title><source>Clin Exp Allergy</source><year>2015</year><volume>45</volume><issue>5</issue><fpage>872</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1111/cea.12476</pub-id><pub-id pub-id-type="pmid">25495772</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Campo P, Rond&#x000f3;n C, Gould HJ, Barrionuevo E, Gevaert P, Blanca M. Local IgE in non-allergic rhinitis. Clin Exp Allergy. 2015;45(5):872&#x02013;81.<pub-id pub-id-type="pmid">25495772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Campo</surname><given-names>P</given-names></name><name><surname>Salas</surname><given-names>M</given-names></name><name><surname>Blanca-L&#x000f3;pez</surname><given-names>N</given-names></name><name><surname>Rond&#x000f3;n</surname><given-names>C</given-names></name></person-group><article-title>Local allergic rhinitis</article-title><source>Immunol Allergy Clin North Am</source><year>2016</year><volume>36</volume><issue>2</issue><fpage>321</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.iac.2015.12.008</pub-id><pub-id pub-id-type="pmid">27083105</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Campo P, Salas M, Blanca-L&#x000f3;pez N, Rond&#x000f3;n C. Local allergic rhinitis. Immunol Allergy Clin North Am. 2016;36(2):321&#x02013;32.<pub-id pub-id-type="pmid">27083105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Dykewicz</surname><given-names>MS</given-names></name><name><surname>Wallace</surname><given-names>DV</given-names></name><name><surname>Amrol</surname><given-names>DJ</given-names></name><name><surname>Baroody</surname><given-names>FM</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Craig</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Rhinitis 2020: a practice parameter update</article-title><source>J Allergy Clin Immunol</source><year>2020</year><volume>146</volume><issue>4</issue><fpage>721</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2020.07.007</pub-id><pub-id pub-id-type="pmid">32707227</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721&#x02013;67.<pub-id pub-id-type="pmid">32707227</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Rond&#x000f3;n</surname><given-names>C</given-names></name><name><surname>Campo</surname><given-names>P</given-names></name><name><surname>Zambonino</surname><given-names>MA</given-names></name><name><surname>Blanca-Lopez</surname><given-names>N</given-names></name><name><surname>Torres</surname><given-names>MJ</given-names></name><name><surname>Melendez</surname><given-names>L</given-names></name><name><surname>Herrera</surname><given-names>R</given-names></name><name><surname>Gu&#x000e9;ant-Rodriguez</surname><given-names>RM</given-names></name><name><surname>Gu&#x000e9;ant</surname><given-names>JL</given-names></name><name><surname>Canto</surname><given-names>G</given-names></name><name><surname>Blanca</surname><given-names>M</given-names></name></person-group><article-title>Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis</article-title><source>J Allergy Clin Immunol</source><year>2014</year><volume>133</volume><issue>4</issue><fpage>1026</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.10.034</pub-id><pub-id pub-id-type="pmid">24332860</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Rond&#x000f3;n C, Campo P, Zambonino MA, Blanca-Lopez N, Torres MJ, Melendez L, Herrera R, Gu&#x000e9;ant-Rodriguez RM, Gu&#x000e9;ant JL, Canto G, Blanca M. Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis. J Allergy Clin Immunol. 2014;133(4):1026&#x02013;31.<pub-id pub-id-type="pmid">24332860</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Demoly</surname><given-names>P</given-names></name><name><surname>Boss&#x000e9;</surname><given-names>I</given-names></name><name><surname>Maigret</surname><given-names>P</given-names></name></person-group><article-title>Perception and control of allergic rhinitis in primary care</article-title><source>NPJ Prim Care Respir Med</source><year>2020</year><volume>30</volume><issue>1</issue><fpage>37</fpage><pub-id pub-id-type="doi">10.1038/s41533-020-00195-8</pub-id><pub-id pub-id-type="pmid">32820169</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Demoly P, Boss&#x000e9; I, Maigret P. Perception and control of allergic rhinitis in primary care. NPJ Prim Care Respir Med. 2020;30(1):37.<pub-id pub-id-type="pmid">32820169</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Guerra</surname><given-names>S</given-names></name><name><surname>Sherrill</surname><given-names>D</given-names></name><name><surname>Martinez</surname><given-names>F</given-names></name><name><surname>Barbee</surname><given-names>RA</given-names></name></person-group><article-title>Rhinitis as an independent risk factor for adult-onset asthma</article-title><source>J Allergy Clin Immunol</source><year>2002</year><volume>109</volume><issue>3</issue><fpage>419</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1067/mai.2002.121701</pub-id><pub-id pub-id-type="pmid">11897985</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Guerra S, Sherrill D, Martinez F, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002;109(3):419&#x02013;25.<pub-id pub-id-type="pmid">11897985</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>E</given-names></name><name><surname>Diemer</surname><given-names>FB</given-names></name><name><surname>Poyser</surname><given-names>J</given-names></name><name><surname>Rice</surname><given-names>V</given-names></name><name><surname>Jean</surname><given-names>LG</given-names></name><name><surname>Britt</surname><given-names>V</given-names></name></person-group><article-title>Asthma and rhinosinusitis prevalence in a Baltimore city public housing complex [abstract]</article-title><source>J Allergy Clin Immunol</source><year>2001</year><volume>107</volume><fpage>S280</fpage></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Horowitz E, Diemer FB, Poyser J, Rice V, Jean LG, Britt V. Asthma and rhinosinusitis prevalence in a Baltimore city public housing complex [abstract]. J Allergy Clin Immunol. 2001;107:S280.</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Kapsali</surname><given-names>T</given-names></name><name><surname>Horowitz</surname><given-names>E</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name></person-group><article-title>Rhinitis is ubiquitous in allergic asthmatics [abstract]</article-title><source>J Allergy Clin Immunol</source><year>1997</year><volume>99</volume><fpage>S138</fpage></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kapsali T, Horowitz E, Togias A. Rhinitis is ubiquitous in allergic asthmatics [abstract]. J Allergy Clin Immunol. 1997;99:S138.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Leynaert</surname><given-names>B</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Neukirch</surname><given-names>C</given-names></name><name><surname>Liard</surname><given-names>R</given-names></name><name><surname>Neukirch</surname><given-names>F</given-names></name></person-group><article-title>Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey</article-title><source>J Allergy Clin Immunol</source><year>1999</year><volume>104</volume><issue>2 Pt 1</issue><fpage>301</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/S0091-6749(99)70370-2</pub-id><pub-id pub-id-type="pmid">10452748</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol. 1999;104(2 Pt 1):301&#x02013;4.<pub-id pub-id-type="pmid">10452748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>SK</given-names></name><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Toskala</surname><given-names>E</given-names></name><name><surname>Orlandi</surname><given-names>RR</given-names></name><name><surname>Akdis</surname><given-names>CA</given-names></name><name><surname>Alt</surname><given-names>JA</given-names></name><etal/></person-group><article-title>International consensus statement on allergy and rhinology: allergic rhinitis</article-title><source>Int Forum Allergy Rhinol</source><year>2018</year><volume>8</volume><issue>2</issue><fpage>108</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">29438602</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108&#x02013;352.<pub-id pub-id-type="pmid">29438602</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">The American Academy of Otolaryngology&#x02014;Head and Neck Surgery Foundation (AAO-HNSF). Choosing wisely; 2019. <ext-link ext-link-type="uri" xlink:href="https://www.entnet.org/about-us/campaigns/choosing-wisely/">https://www.entnet.org/about-us/campaigns/choosing-wisely/</ext-link>. Accessed 19 June 2024.</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Guarnieri</surname><given-names>G</given-names></name><name><surname>Olivieri</surname><given-names>B</given-names></name><name><surname>Senna</surname><given-names>G</given-names></name><name><surname>Vianello</surname><given-names>A</given-names></name></person-group><article-title>Relative humidity and its impact on the immune system and infections</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>11</issue><fpage>9456</fpage><pub-id pub-id-type="doi">10.3390/ijms24119456</pub-id><pub-id pub-id-type="pmid">37298409</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Guarnieri G, Olivieri B, Senna G, Vianello A. Relative humidity and its impact on the immune system and infections. Int J Mol Sci. 2023;24(11):9456.<pub-id pub-id-type="pmid">37298409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Yang</surname><given-names>CP</given-names></name><name><surname>Ku</surname><given-names>MS</given-names></name><name><surname>Sun</surname><given-names>HL</given-names></name><name><surname>Lue</surname><given-names>KH</given-names></name></person-group><article-title>Efficacy of nasal irrigation in the treatment of acute sinusitis in children</article-title><source>Int J Pediatr Otorhinolaryngol</source><year>2009</year><volume>73</volume><issue>12</issue><fpage>1696</fpage><lpage>1701</lpage><pub-id pub-id-type="doi">10.1016/j.ijporl.2009.09.001</pub-id><pub-id pub-id-type="pmid">19786306</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Wang YH, Yang CP, Ku MS, Sun HL, Lue KH. Efficacy of nasal irrigation in the treatment of acute sinusitis in children. Int J Pediatr Otorhinolaryngol. 2009;73(12):1696&#x02013;701.<pub-id pub-id-type="pmid">19786306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Sha</surname><given-names>Q</given-names></name><name><surname>Zuo</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name></person-group><article-title>Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children</article-title><source>ORL J Otorhinolaryngol Relat Spec</source><year>2009</year><volume>71</volume><issue>1</issue><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1159/000178165</pub-id><pub-id pub-id-type="pmid">19047814</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Li H, Sha Q, Zuo K, Jiang H, Cheng L, Shi J, Xu G. Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children. ORL J Otorhinolaryngol Relat Spec. 2009;71(1):50&#x02013;5.<pub-id pub-id-type="pmid">19047814</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Head</surname><given-names>K</given-names></name><name><surname>Snidvongs</surname><given-names>K</given-names></name><name><surname>Glew</surname><given-names>S</given-names></name><name><surname>Scadding</surname><given-names>G</given-names></name><name><surname>Schilder</surname><given-names>AG</given-names></name><name><surname>Philpott</surname><given-names>C</given-names></name><name><surname>Hopkins</surname><given-names>C</given-names></name></person-group><article-title>Saline irrigation for allergic rhinitis</article-title><source>Cochrane Database Syst Rev</source><year>2018</year><volume>6</volume><issue>6</issue><fpage>CD012597</fpage><pub-id pub-id-type="pmid">29932206</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Head K, Snidvongs K, Glew S, Scadding G, Schilder AG, Philpott C, Hopkins C. Saline irrigation for allergic rhinitis. Cochrane Database Syst Rev. 2018;6(6):CD012597.<pub-id pub-id-type="pmid">29932206</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Hermelingmeier</surname><given-names>KE</given-names></name><name><surname>Weber</surname><given-names>RK</given-names></name><name><surname>Hellmich</surname><given-names>M</given-names></name><name><surname>Heubach</surname><given-names>CP</given-names></name><name><surname>M&#x000f6;sges</surname><given-names>R</given-names></name></person-group><article-title>Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis</article-title><source>Am J Rhin Allergy</source><year>2012</year><volume>26</volume><issue>5</issue><fpage>e119</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.2500/ajra.2012.26.3787</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hermelingmeier KE, Weber RK, Hellmich M, Heubach CP, M&#x000f6;sges R. Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. Am J Rhin Allergy. 2012;26(5):e119&#x02013;25.</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. How to prevent <italic>Naegleria fowleri</italic> infection when rinsing sinuses or nasal passages May 13, 2024. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/naegleria/prevention/sinus-rinsing.html?CDC_AAref_Val=https://www.cdc.gov/parasites/naegleria/sinus-rinsing.html">https://www.cdc.gov/naegleria/prevention/sinus-rinsing.html?CDC_AAref_Val=https://www.cdc.gov/parasites/naegleria/sinus-rinsing.html</ext-link>. Accessed 19 June 2024.</mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">US Food and Drug Administration. Is rinsing your sinuses with neti pots safe? Updated May 10, 2023. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/consumers/consumer-updates/rinsing-your-sinuses-neti-pots-safe">https://www.fda.gov/consumers/consumer-updates/rinsing-your-sinuses-neti-pots-safe</ext-link>. Accessed 19 June 2024.</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Sch&#x000fc;nemann</surname><given-names>HJ</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Erhola</surname><given-names>M</given-names></name><name><surname>Hellings</surname><given-names>PW</given-names></name><collab>Allergic Rhinitis and Its Impact on Asthma Working Group</collab><etal/></person-group><article-title>Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence</article-title><source>J Allergy Clin Immunol</source><year>2020</year><volume>145</volume><issue>1</issue><fpage>70</fpage><lpage>80.e3</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.06.049</pub-id><pub-id pub-id-type="pmid">31627910</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bousquet J, Sch&#x000fc;nemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, Allergic Rhinitis and Its Impact on Asthma Working Group, et al. Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3.<pub-id pub-id-type="pmid">31627910</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Fein</surname><given-names>MN</given-names></name><name><surname>Fischer</surname><given-names>DA</given-names></name><name><surname>O'Keefe</surname><given-names>AW</given-names></name><name><surname>Sussman</surname><given-names>GL</given-names></name></person-group><article-title>CSACI position statement: Newer generation H<sub>1</sub>-antihistamines are safer than first-generation H<sub>1</sub>-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria</article-title><source>Allergy Asthma Clin Immunol</source><year>2019</year><volume>15</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s13223-019-0375-9</pub-id><pub-id pub-id-type="pmid">31582993</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Fein MN, Fischer DA, O&#x02019;Keefe AW, Sussman GL. CSACI position statement: Newer generation H<sub>1</sub>-antihistamines are safer than first-generation H<sub>1</sub>-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61.<pub-id pub-id-type="pmid">31582993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Yanez</surname><given-names>A</given-names></name><name><surname>Rodrigo</surname><given-names>GJ</given-names></name></person-group><article-title>Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis</article-title><source>Ann Allergy Asthma Immunol</source><year>2002</year><volume>89</volume><issue>5</issue><fpage>479</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/S1081-1206(10)62085-6</pub-id><pub-id pub-id-type="pmid">12452206</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89(5):479&#x02013;84.<pub-id pub-id-type="pmid">12452206</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Pullerits</surname><given-names>T</given-names></name><name><surname>Praks</surname><given-names>L</given-names></name><name><surname>Ristioja</surname><given-names>V</given-names></name><name><surname>L&#x000f6;tvall</surname><given-names>J</given-names></name></person-group><article-title>Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis</article-title><source>J Allergy Clin Immunol</source><year>2002</year><volume>109</volume><issue>6</issue><fpage>949</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1067/mai.2002.124467</pub-id><pub-id pub-id-type="pmid">12063523</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Pullerits T, Praks L, Ristioja V, L&#x000f6;tvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(6):949&#x02013;55.<pub-id pub-id-type="pmid">12063523</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AM</given-names></name><name><surname>O&#x02019;Byrne</surname><given-names>PM</given-names></name><name><surname>Parameswaran</surname><given-names>K</given-names></name></person-group><article-title>Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis</article-title><source>Am J Med</source><year>2004</year><volume>116</volume><issue>5</issue><fpage>338</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2003.10.030</pub-id><pub-id pub-id-type="pmid">14984820</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Wilson AM, O&#x02019;Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116(5):338&#x02013;44.<pub-id pub-id-type="pmid">14984820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>JM</given-names></name><name><surname>Abramson</surname><given-names>MJ</given-names></name><name><surname>Puy</surname><given-names>RM</given-names></name></person-group><article-title>Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials</article-title><source>BMJ</source><year>1998</year><volume>317</volume><issue>7173</issue><fpage>1624</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1136/bmj.317.7173.1624</pub-id><pub-id pub-id-type="pmid">9848901</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998;317(7173):1624&#x02013;9.<pub-id pub-id-type="pmid">9848901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>DeWester</surname><given-names>J</given-names></name><name><surname>Philpot</surname><given-names>EE</given-names></name><name><surname>Westlund</surname><given-names>RE</given-names></name><name><surname>Cook</surname><given-names>CK</given-names></name><name><surname>Rickard</surname><given-names>KA</given-names></name></person-group><article-title>The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis</article-title><source>Allergy Asthma Proc</source><year>2003</year><volume>24</volume><issue>5</issue><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">14619333</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">DeWester J, Philpot EE, Westlund RE, Cook CK, Rickard KA. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24(5):331&#x02013;7.<pub-id pub-id-type="pmid">14619333</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>DI</given-names></name><name><surname>Levy</surname><given-names>AL</given-names></name><name><surname>Hampel</surname><given-names>FC</given-names></name><name><surname>Baidoo</surname><given-names>CA</given-names></name><name><surname>Cook</surname><given-names>CK</given-names></name><name><surname>Philpot</surname><given-names>EE</given-names></name><name><surname>Rickard</surname><given-names>KA</given-names></name></person-group><article-title>Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis</article-title><source>Clin Exp Allergy</source><year>2004</year><volume>34</volume><issue>6</issue><fpage>952</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2004.01952.x</pub-id><pub-id pub-id-type="pmid">15196285</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Bernstein DI, Levy AL, Hampel FC, Baidoo CA, Cook CK, Philpot EE, Rickard KA. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(6):952&#x02013;7.<pub-id pub-id-type="pmid">15196285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>WT</given-names></name><name><surname>Becker</surname><given-names>AB</given-names></name><name><surname>Simons</surname><given-names>FER</given-names></name></person-group><article-title>Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway hyperresponsiveness</article-title><source>J Allergy Clin Immunol</source><year>1993</year><volume>91</volume><issue>1 Pt 1</issue><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/0091-6749(93)90301-U</pub-id><pub-id pub-id-type="pmid">8423275</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Watson WT, Becker AB, Simons FER. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway hyperresponsiveness. J Allergy Clin Immunol. 1993;91(1 Pt 1):97&#x02013;101.<pub-id pub-id-type="pmid">8423275</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Skoner</surname><given-names>DP</given-names></name><name><surname>Rachelefsky</surname><given-names>GS</given-names></name><name><surname>Meltzer</surname><given-names>EO</given-names></name><name><surname>Chervinsky</surname><given-names>P</given-names></name><name><surname>Morris</surname><given-names>RM</given-names></name><name><surname>Seltzer</surname><given-names>JM</given-names></name><name><surname>Storms</surname><given-names>WW</given-names></name><name><surname>Wood</surname><given-names>RA</given-names></name></person-group><article-title>Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate</article-title><source>Pediatrics</source><year>2000</year><volume>105</volume><fpage>E23</fpage><pub-id pub-id-type="doi">10.1542/peds.105.2.e23</pub-id><pub-id pub-id-type="pmid">10654983</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105:E23.<pub-id pub-id-type="pmid">10654983</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>DB</given-names></name><name><surname>Meltzer</surname><given-names>EO</given-names></name><name><surname>Lemanske</surname><given-names>RF</given-names><suffix>Jr</suffix></name><name><surname>Philpot</surname><given-names>EE</given-names></name><name><surname>Faris</surname><given-names>MA</given-names></name><name><surname>Kral</surname><given-names>KM</given-names></name><name><surname>Prillaman</surname><given-names>BA</given-names></name><name><surname>Rickard</surname><given-names>KA</given-names></name></person-group><article-title>No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year</article-title><source>Allergy Asthma Proc</source><year>2002</year><volume>23</volume><issue>6</issue><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">12528607</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407&#x02013;13.<pub-id pub-id-type="pmid">12528607</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Agertoft</surname><given-names>L</given-names></name><name><surname>Pedersen</surname><given-names>S</given-names></name></person-group><article-title>Effect of long-term treatment with inhaled budesonide on adult height in children with asthma</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><issue>15</issue><fpage>1064</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1056/NEJM200010123431502</pub-id><pub-id pub-id-type="pmid">11027740</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343(15):1064&#x02013;9.<pub-id pub-id-type="pmid">11027740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Schenkel</surname><given-names>EJ</given-names></name><name><surname>Skoner</surname><given-names>DP</given-names></name><name><surname>Bronsky</surname><given-names>EA</given-names></name><name><surname>Miller</surname><given-names>SD</given-names></name><name><surname>Pearlman</surname><given-names>DS</given-names></name><name><surname>Rooklin</surname><given-names>A</given-names></name><name><surname>Rosen</surname><given-names>JP</given-names></name><name><surname>Ruff</surname><given-names>ME</given-names></name><name><surname>Vandewalker</surname><given-names>ML</given-names></name><name><surname>Wanderer</surname><given-names>A</given-names></name><name><surname>Damaraju</surname><given-names>CV</given-names></name><name><surname>Nolop</surname><given-names>KB</given-names></name><name><surname>Mesarina-Wicki</surname><given-names>B</given-names></name></person-group><article-title>Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray</article-title><source>Pediatrics</source><year>2000</year><volume>105</volume><fpage>E22</fpage><pub-id pub-id-type="doi">10.1542/peds.105.2.e22</pub-id><pub-id pub-id-type="pmid">10654982</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vandewalker ML, Wanderer A, Damaraju CV, Nolop KB, Mesarina-Wicki B. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105:E22.<pub-id pub-id-type="pmid">10654982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Lund</surname><given-names>VJ</given-names></name><name><surname>van Cauwenberge</surname><given-names>P</given-names></name><name><surname>Bremard-Oury</surname><given-names>C</given-names></name><name><surname>Mounedji</surname><given-names>N</given-names></name><name><surname>Stevens</surname><given-names>MT</given-names></name><name><surname>El-Akkad</surname><given-names>T</given-names></name></person-group><article-title>Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial</article-title><source>Allergy</source><year>2003</year><volume>58</volume><issue>8</issue><fpage>733</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1034/j.1398-9995.2003.00076.x</pub-id><pub-id pub-id-type="pmid">12859551</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Bousquet J, Lund VJ, van Cauwenberge P, Bremard-Oury C, Mounedji N, Stevens MT, El-Akkad T. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy. 2003;58(8):733&#x02013;41.<pub-id pub-id-type="pmid">12859551</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>W</given-names></name><name><surname>Bernstein</surname><given-names>J</given-names></name><name><surname>Lieberman</surname><given-names>P</given-names></name><name><surname>Meltzer</surname><given-names>E</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Munzel</surname><given-names>U</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name></person-group><article-title>A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis</article-title><source>J Allergy Clin Immunol</source><year>2012</year><volume>129</volume><issue>5</issue><fpage>1282</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2012.01.077</pub-id><pub-id pub-id-type="pmid">22418065</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, Munzel U, Bousquet J. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282&#x02013;9.<pub-id pub-id-type="pmid">22418065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Meltzer</surname><given-names>E</given-names></name><name><surname>Ratner</surname><given-names>P</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Carr</surname><given-names>W</given-names></name><name><surname>Berger</surname><given-names>W</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Hadley</surname><given-names>J</given-names></name><name><surname>Lieberman</surname><given-names>P</given-names></name><name><surname>Hampel</surname><given-names>FC</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><name><surname>Munzel</surname><given-names>U</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Scadding</surname><given-names>G</given-names></name><name><surname>Virchow</surname><given-names>JC</given-names></name><name><surname>Wahn</surname><given-names>U</given-names></name><name><surname>Murray</surname><given-names>R</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name></person-group><article-title>Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis</article-title><source>Int Arch Allergy Immunol</source><year>2013</year><volume>161</volume><issue>4</issue><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1159/000351404</pub-id><pub-id pub-id-type="pmid">23652808</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, Hadley J, Lieberman P, Hampel FC, Mullol J, Munzel U, Price D, Scadding G, Virchow JC, Wahn U, Murray R, Bousquet J. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161(4):369&#x02013;77.<pub-id pub-id-type="pmid">23652808</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>W</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Carr</surname><given-names>W</given-names></name><name><surname>Hellings</surname><given-names>P</given-names></name><name><surname>Munzel</surname><given-names>U</given-names></name><name><surname>Scadding</surname><given-names>G</given-names></name><name><surname>Lieberman</surname><given-names>P</given-names></name></person-group><article-title>A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis</article-title><source>J Investig Allergol Clin Immunol</source><year>2013</year><volume>23</volume><issue>7</issue><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">24654314</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, Carr W, Hellings P, Munzel U, Scadding G, Lieberman P. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495&#x02013;503.<pub-id pub-id-type="pmid">24654314</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>WE</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Lieberman</surname><given-names>P</given-names></name><name><surname>Hadley</surname><given-names>J</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Munzel</surname><given-names>U</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name></person-group><article-title>Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis</article-title><source>J Allergy Clin Immunol Pract</source><year>2014</year><volume>2</volume><issue>2</issue><fpage>179</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2013.09.019</pub-id><pub-id pub-id-type="pmid">24607046</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, Bhatia S. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2(2):179&#x02013;85.<pub-id pub-id-type="pmid">24607046</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Pullerits</surname><given-names>T</given-names></name><name><surname>Praks</surname><given-names>L</given-names></name><name><surname>Skoogh</surname><given-names>BE</given-names></name><name><surname>Ani</surname><given-names>R</given-names></name><name><surname>L&#x000f6;tvall</surname><given-names>J</given-names></name></person-group><article-title>Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><issue>6</issue><fpage>1814</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.159.6.9810016</pub-id><pub-id pub-id-type="pmid">10351924</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Pullerits T, Praks L, Skoogh BE, Ani R, L&#x000f6;tvall J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med. 1999;159(6):1814&#x02013;8.<pub-id pub-id-type="pmid">10351924</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Ratner</surname><given-names>PH</given-names></name><name><surname>Howland</surname><given-names>WC</given-names><suffix>III</suffix></name><name><surname>Arastu</surname><given-names>R</given-names></name><name><surname>Philpot</surname><given-names>EE</given-names></name><name><surname>Klein</surname><given-names>KC</given-names></name><name><surname>Baidoo</surname><given-names>CA</given-names></name><name><surname>Faris</surname><given-names>MA</given-names></name><name><surname>Rickard</surname><given-names>KA</given-names></name></person-group><article-title>Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast</article-title><source>Ann Allergy Asthma Immunol</source><year>2003</year><volume>90</volume><issue>5</issue><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/S1081-1206(10)61847-9</pub-id><pub-id pub-id-type="pmid">12775135</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Ratner PH, Howland WC III, Arastu R, Philpot EE, Klein KC, Baidoo CA, Faris MA, Rickard KA. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol. 2003;90(5):536&#x02013;42.<pub-id pub-id-type="pmid">12775135</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AM</given-names></name><name><surname>Dempsey</surname><given-names>OJ</given-names></name><name><surname>Sims</surname><given-names>EJ</given-names></name><name><surname>Lipworth</surname><given-names>BJ</given-names></name></person-group><article-title>A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma</article-title><source>Clin Exp Allergy</source><year>2001</year><volume>31</volume><issue>4</issue><fpage>616</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2222.2001.01088.x</pub-id><pub-id pub-id-type="pmid">11359431</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy. 2001;31(4):616&#x02013;24.<pub-id pub-id-type="pmid">11359431</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AM</given-names></name><name><surname>Orr</surname><given-names>LC</given-names></name><name><surname>Sims</surname><given-names>EJ</given-names></name><name><surname>Lipworth</surname><given-names>BJ</given-names></name></person-group><article-title>Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis</article-title><source>Clin Exp Allergy</source><year>2001</year><volume>31</volume><issue>1</issue><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2001.00964.x</pub-id><pub-id pub-id-type="pmid">11167952</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy. 2001;31(1):61&#x02013;8.<pub-id pub-id-type="pmid">11167952</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>G</given-names></name><name><surname>Pacor</surname><given-names>ML</given-names></name><name><surname>Pellitteri</surname><given-names>ME</given-names></name><name><surname>Morici</surname><given-names>G</given-names></name><name><surname>Di Gregoli</surname><given-names>A</given-names></name><name><surname>Lo Bianco</surname><given-names>C</given-names></name><name><surname>Ditta</surname><given-names>V</given-names></name><name><surname>Martinelli</surname><given-names>N</given-names></name><name><surname>Candore</surname><given-names>G</given-names></name><name><surname>Mansueto</surname><given-names>P</given-names></name><name><surname>Rini</surname><given-names>GB</given-names></name><name><surname>Corrocher</surname><given-names>R</given-names></name><name><surname>Caruso</surname><given-names>C</given-names></name></person-group><article-title>Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in monotherapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis</article-title><source>Clin Exp Allergy</source><year>2004</year><volume>34</volume><issue>2</issue><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2004.01877.x</pub-id><pub-id pub-id-type="pmid">14987306</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C, Ditta V, Martinelli N, Candore G, Mansueto P, Rini GB, Corrocher R, Caruso C. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in monotherapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(2):259&#x02013;67.<pub-id pub-id-type="pmid">14987306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>SM</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Till</surname><given-names>SJ</given-names></name><name><surname>Roberts</surname><given-names>G</given-names></name><name><surname>Corrigan</surname><given-names>CJ</given-names></name><name><surname>Leech</surname><given-names>SC</given-names></name><name><surname>Krishna</surname><given-names>MT</given-names></name><name><surname>Rajakulasingham</surname><given-names>RK</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Chantrell</surname><given-names>J</given-names></name><name><surname>Dixon</surname><given-names>L</given-names></name><name><surname>Frew</surname><given-names>AJ</given-names></name><name><surname>Nasser</surname><given-names>SM</given-names></name><collab>British Society for Allergy and Clinical Immunology</collab></person-group><article-title>Immunotherapy for allergic rhinitis</article-title><source>Clin Exp Allergy</source><year>2011</year><volume>41</volume><issue>9</issue><fpage>1177</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2011.03794.x</pub-id><pub-id pub-id-type="pmid">21848757</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Walker SM, Durham SR, Till SJ, Roberts G, Corrigan CJ, Leech SC, Krishna MT, Rajakulasingham RK, Williams A, Chantrell J, Dixon L, Frew AJ, Nasser SM, British Society for Allergy and Clinical Immunology. Immunotherapy for allergic rhinitis. Clin Exp Allergy. 2011;41(9):1177&#x02013;200.<pub-id pub-id-type="pmid">21848757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Frew</surname><given-names>AJ</given-names></name></person-group><article-title>Allergen immunotherapy</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>125</volume><issue>2 Suppl 2</issue><fpage>S306</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.10.064</pub-id><pub-id pub-id-type="pmid">20176266</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S306-313.<pub-id pub-id-type="pmid">20176266</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Canadian Society of Allergy and Clinical Immunology. Immunotherapy manual; 2024.</mixed-citation></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Calderon</surname><given-names>MA</given-names></name><name><surname>Alves</surname><given-names>B</given-names></name><name><surname>Jacobson</surname><given-names>M</given-names></name><name><surname>Hurwitz</surname><given-names>B</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Durham</surname><given-names>S</given-names></name></person-group><article-title>Allergen injection immunotherapy for seasonal allergic rhinitis</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>1</volume><fpage>CD001936</fpage></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1:CD001936.</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Acarizax (standardized allergen extract, house dust mites) product monograph. ALK-Abello A/S. December 29, 2022.</mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Grastek (standardized allergen extract, Timothy Grass) product monograph. ALK-Abello A/S. May 17, 2017.</mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Itulatek (standardized allergen extract, White Birch) product monograph. ALK-Abello A/S. January 13, 2022.</mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Ragwitek (standardized allergen extract, Short Ragweed) product monograph. ALK-Abello A/S. December 18, 2020.</mixed-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Oralair (grass pollen allergen extract) product monograph. Stallergenes Canada Inc. November 18, 2016.</mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Walker</surname><given-names>SM</given-names></name><name><surname>Varga</surname><given-names>EM</given-names></name><name><surname>Jacobson</surname><given-names>MR</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>F</given-names></name><name><surname>Noble</surname><given-names>W</given-names></name><name><surname>Till</surname><given-names>SJ</given-names></name><name><surname>Hamid</surname><given-names>QA</given-names></name><name><surname>Nouri-Aria</surname><given-names>KT</given-names></name></person-group><article-title>Long-term clinical efficacy of grass pollen immunotherapy</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><issue>7</issue><fpage>468</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1056/NEJM199908123410702</pub-id><pub-id pub-id-type="pmid">10441602</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Durham SR, Walker SM, Varga EM, Jacobson MR, O&#x02019;Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med. 1999;341(7):468&#x02013;75.<pub-id pub-id-type="pmid">10441602</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Didier</surname><given-names>A</given-names></name><name><surname>Malling</surname><given-names>HJ</given-names></name><name><surname>Worm</surname><given-names>M</given-names></name><name><surname>Horak</surname><given-names>F</given-names></name><name><surname>Sussman</surname><given-names>G</given-names></name><name><surname>Melac</surname><given-names>M</given-names></name><name><surname>Souli&#x000e9;</surname><given-names>S</given-names></name><name><surname>Zeldin</surname><given-names>RK</given-names></name></person-group><article-title>Post-treatment efficacy of discontinuous treatment with 300 IR 5 grass pollen sublingual tablet in adults with grass pollen induced allergic rhinoconjunctivitis</article-title><source>Clin Exp Allerg</source><year>2013</year><volume>43</volume><fpage>568</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1111/cea.12100</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Didier A, Malling HJ, Worm M, Horak F, Sussman G, Melac M, Souli&#x000e9; S, Zeldin RK. Post-treatment efficacy of discontinuous treatment with 300 IR 5 grass pollen sublingual tablet in adults with grass pollen induced allergic rhinoconjunctivitis. Clin Exp Allerg. 2013;43:568&#x02013;77.</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Emminger</surname><given-names>W</given-names></name><name><surname>Kapp</surname><given-names>A</given-names></name><name><surname>de Monchy</surname><given-names>JG</given-names></name><name><surname>Rak</surname><given-names>S</given-names></name><name><surname>Scadding</surname><given-names>GK</given-names></name><etal/></person-group><article-title>R. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial</article-title><source>J Allergy Clin Immunol</source><year>2012</year><volume>129</volume><issue>3</issue><fpage>717</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2011.12.973</pub-id><pub-id pub-id-type="pmid">22285278</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. R. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717&#x02013;25.<pub-id pub-id-type="pmid">22285278</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>PA</given-names></name><name><surname>Borer-Reinhold</surname><given-names>M</given-names></name><name><surname>Heijnen</surname><given-names>IA</given-names></name><name><surname>Gnehm</surname><given-names>HP</given-names></name></person-group><article-title>Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood</article-title><source>Allergy</source><year>2006</year><volume>61</volume><issue>2</issue><fpage>198</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2006.01011.x</pub-id><pub-id pub-id-type="pmid">16409196</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006;61(2):198&#x02013;201.<pub-id pub-id-type="pmid">16409196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Shamji</surname><given-names>MH</given-names></name></person-group><article-title>Allergen immunotherapy: past, present and future</article-title><source>Nat Rev Immunol</source><year>2023</year><volume>23</volume><issue>5</issue><fpage>317</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00786-1</pub-id><pub-id pub-id-type="pmid">36253555</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2023;23(5):317&#x02013;28.<pub-id pub-id-type="pmid">36253555</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Penagos</surname><given-names>M</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name></person-group><article-title>Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy</article-title><source>Allergy Asthma Proc</source><year>2022</year><volume>43</volume><issue>4</issue><fpage>292</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.2500/aap.2022.43.220026</pub-id><pub-id pub-id-type="pmid">35818157</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Penagos M, Durham SR. Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy. Allergy Asthma Proc. 2022;43(4):292&#x02013;8.<pub-id pub-id-type="pmid">35818157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Canonica</surname><given-names>G</given-names></name><name><surname>Cox</surname><given-names>L</given-names></name><name><surname>Pawankar</surname><given-names>R</given-names></name><name><surname>Baena-Cagnani</surname><given-names>CE</given-names></name><name><surname>Blaiss</surname><given-names>M</given-names></name><name><surname>Bonini</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sublingual immunotherapy: World Allergy Organization position paper 2013 update</article-title><source>World Allergy Organ J</source><year>2014</year><volume>7</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1939-4551-7-6</pub-id><pub-id pub-id-type="pmid">24679069</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Canonica G, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.<pub-id pub-id-type="pmid">24679069</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Scadding</surname><given-names>GW</given-names></name><name><surname>Calderon</surname><given-names>MA</given-names></name><name><surname>Shamji</surname><given-names>MH</given-names></name><name><surname>Eifan</surname><given-names>AO</given-names></name><name><surname>Penagos</surname><given-names>M</given-names></name><name><surname>Dumitru</surname><given-names>F</given-names></name><collab>Immune Tolerance Network GRASS Study Team</collab><etal/></person-group><article-title>Effect of 2 years of treatment with sublingual grass pollen&#x000a0;immunotherapy&#x000a0;on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: The GRASS Randomized Clinical Trial</article-title><source>JAMA</source><year>2017</year><volume>317</volume><issue>6</issue><fpage>615</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.21040</pub-id><pub-id pub-id-type="pmid">28196255</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, Immune Tolerance Network GRASS Study Team, et al. Effect of 2 years of treatment with sublingual grass pollen&#x000a0;immunotherapy&#x000a0;on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: The GRASS Randomized Clinical Trial. JAMA. 2017;317(6):615&#x02013;25.<pub-id pub-id-type="pmid">28196255</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>JK</given-names></name><name><surname>Seikaly</surname><given-names>H</given-names></name><name><surname>Calhoun</surname><given-names>KH</given-names></name></person-group><article-title>Extended use of topical nasal decongestants</article-title><source>Laryngoscope</source><year>1997</year><volume>107</volume><issue>1</issue><fpage>40</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1097/00005537-199701000-00010</pub-id><pub-id pub-id-type="pmid">9001263</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Yoo JK, Seikaly H, Calhoun KH. Extended use of topical nasal decongestants. Laryngoscope. 1997;107(1):40&#x02013;3.<pub-id pub-id-type="pmid">9001263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>J</given-names></name><name><surname>Bielory</surname><given-names>L</given-names></name></person-group><article-title>Complementary and alternative therapy (CAM) in the treatment of allergic rhinitis in the treatment of allergic rhinitis</article-title><source>Curr Allergy Asthma Rep</source><year>2014</year><volume>14</volume><issue>12</issue><fpage>479</fpage><pub-id pub-id-type="doi">10.1007/s11882-014-0479-8</pub-id><pub-id pub-id-type="pmid">25269403</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Kern J, Bielory L. Complementary and alternative therapy (CAM) in the treatment of allergic rhinitis in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2014;14(12):479.<pub-id pub-id-type="pmid">25269403</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>